[1]曾小兵,朱長東,謝寶強.利拉魯肽對首診2型糖尿病患者血糖、血脂及T細胞亞群的影響[J].醫學信息,2019,(22):125-127.[doi:10.3969/j.issn.1006-1959.2019.22.041]
 ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2019,(22):125-127.[doi:10.3969/j.issn.1006-1959.2019.22.041]
點擊復制

利拉魯肽對首診2型糖尿病患者血糖、血脂及T細胞亞群的影響()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
125-127
欄目:
藥物與臨床
出版日期:
2019-11-15

文章信息/Info

Title:
Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus
文章編號:
1006-1959(2019)22-0125-03
作者:
曾小兵朱長東謝寶強
(贛州市立醫院內分泌科,江西 贛州 341000)
Author(s):
ZENG Xiao-bingZHU Chang-dongXIE Bao-qiang
(Department of Endocrinology,Ganzhou Municipal Hospital,Ganzhou 341000,Jiangxi,China)
關鍵詞:
2型糖尿病利拉魯肽CD4+T細胞亞群
Keywords:
Type 2 diabetesLiraglutideCD4+ T cell subset
分類號:
R587.1
DOI:
10.3969/j.issn.1006-1959.2019.22.041
文獻標志碼:
A
摘要:
目的 探討利拉魯肽治療首診超重或肥胖2型糖尿病患者的效果及其對T細胞亞群的影響。方法 選取2018年2月~2019年6月我院收治的72例確診為2型糖尿病超重或肥胖患者,采用隨機數字表法分為對照組和研究組,每組36例。對照組予以常規治療,研究組在對照組基礎上加用利拉魯肽治療,比較兩組治療前后血糖水平(FPG、BPG、HbA1c)、空腹胰島素+C肽、餐后2h胰島素+C肽水平、BMI、血脂(HDL-C、LDL-C、VLDL-C、TC、TG)以及CD4+、CD4+/CD8+水平。結果 治療后,研究組FPG、BPG、HBA1c水平低于對照組(P<0.05),空腹胰島素、餐后2h胰島素和空腹C肽、餐后2h C肽水平高于對照組(P<0.05);研究組BMI水平低于對照組(P<0.05);研究組TG、TC、LDL-C、VLDL-C水平低于對照組,HDL-C水平高于對照組(P<0.05);研究組CD4+、CD4+/CD8+高于對照組(P<0.05)。結論 利拉魯肽可調節CD4+T細胞亞群平衡,改善胰島素β細胞功能并降低胰島素抵抗,可更好控制2型糖尿病患者血糖水平,改善血脂水平,降低體質量。
Abstract:
Objective To investigate the effect of liraglutide in the treatment of patients with overweight or obesity type 2 diabetes and its effect on T cell subsets. Methods 72 patients with type 2 diabetes who were overweight or obese were enrolled in our hospital from February 2018 to June 2019. They were randomly divided into the control group and the study group, with 36 cases in each group. The control group received routine treatment. The study group was treated with liraglutide on the basis of the control group. The blood glucose levels (FPG, BPG, HbA1c), fasting insulin + C peptide, and postprandial 2h insulin + C peptide levels were compared before and after treatment, BMI, blood lipids (HDL-C, LDL-C, VLDL-C, TC, TG) and CD4+, CD4+/CD8+ levels. Results After treatment, the levels of FPG, BPG and HBA1c in the study group were lower than those in the control group (P<0.05). The levels of fasting insulin, 2h postprandial insulin and fasting C-peptide, and 2h C-peptide after meal were higher than those in the control group (P<0.05). The BMI level of the group was lower than that of the control group (P<0.05). The levels of TG, TC, LDL-C and VLDL-C in the study group were lower than those in the control group, and the HDL-C level was higher than that in the control group (P<0.05). The study group CD4+, CD4+/CD8+ was higher than the control group (P<0.05). Conclusion Liraglutide can regulate the balance of CD4+ T cell subsets, improve insulin β cell function and reduce insulin resistance, which can better control blood glucose levels, improve blood lipid levels and reduce body mass in patients with type 2 diabetes.

參考文獻/References:

[1]Sujanitha V,Sivansuthan S,Selvakaran P,et al.Over-weight, obesity and chronic complications of diabetes mellitus in patients attending Diabetic Centre, Teaching Hospital, Jaffna, Sri Lanka[J].Ceylon Medical Journal,2015,60(3):94. [2]Laakso M,Kuusisto J.Insulin resistance and hyperglycaemia in cardiovascular disease development[J].Nature Reviews Endocrinology,2014,10(5):293-302. [3]Saad MJ,Santos A,Prada PO,et al.Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance[J].Physiology(Bethesda),2016,31(4):283-293. [4]Chen X,Zhang D,Chen X,et al.Oral administration of visceral adipose tissue antigens ameliorates metabolic disorders in mice and eleveates visceral adipose tissue-resident CD4+CD25+Foxp3+regulatory T cells[J].Vaccine,2017,35(35PtB):4412-4620. [5]中華醫學會糖尿病學分會.中國2型糖尿病防治指南(2017年版)[J].中國實用內科雜志,2018,38(4):292-344. [6]周文敬,金京姬,吳英花,等.從對糖耐量正常人群分層探析β細胞功能和胰島素抵抗的發生發展[J].中華內分泌代謝雜志,2017,33(9):741-744. [7]Quan W,Jo EK,Lee MS.Role of pancreatic β-cell death and inflammation in diabetes[J].Diabetes,Obesity and Metabolism,2013,15(3):141-151. [8]黃倩,劉嬋,黃福常,等.利拉魯肽治療新診斷2型糖尿病患者的有效性及安全性[J].河北醫藥,2019,41(12):1821-1824. [9]饒利民,胡立春.利拉魯肽治療初發2型糖尿病效果觀察[J].慢性病學雜志,2019,20(7):1047-1048. [10]曹潔.2型糖尿病輔助性T細胞17(Th17)與調節性T細胞(Treg)失衡與HOMA-IR、HOMA-β的相關性研究[D].山西醫科大學,2019.

相似文獻/References:

[1]黃德斌,章臻翊,章 婷,等.2型糖尿病患者亞臨床甲狀腺功能減退與白蛋白尿的關系研究[J].醫學信息,2018,(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
 HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,(22):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]鄧婷婷,王亞洲,張 紅.口福怡稻治療2型糖尿病的臨床效果研究[J].醫學信息,2018,(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
 DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,(22):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹嵐,侯瑞田,王;,等.Lp-PLA2血小板相關因子與2型糖尿病合并高血壓病的 相關性研究[J].醫學信息,2018,(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,(22):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,鄧正聰.代謝綜合征與腫瘤關系的研究進展[J].醫學信息,2018,(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,(22):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]劉 洪.地特胰島素或甘精胰島素聯合使用口服藥物治療2型糖尿病療效及對體重的影響分析[J].醫學信息,2018,(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
 LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,(22):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]劉 靜.利拉魯肽聯合基礎胰島素對初診2型糖尿病合并肥胖患者 血糖控制及體質量指數的影響[J].醫學信息,2018,(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
 LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Medical Information,2018,(22):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[7]劉靜波,黃 萍,趙 靜.應用微信平臺對初發中青年2型糖尿病患者進行 健康管理模式的研究[J].醫學信息,2018,(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
 LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,(22):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[8]丁 星,趙 暢,張海嚴,等.麥邦數據遠程傳輸型血糖儀臨床測量準確性的評價研究[J].醫學信息,2018,(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
 DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,(22):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[9]梁延洋,程艷娜,華柏慧,等.胃癌合并2型糖尿病術后血糖改善的臨床觀察[J].醫學信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(22):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[10]劉小紅.長效胰島素聯合口服降糖藥治療2型糖尿病的 療效與安全性評價[J].醫學信息,2018,(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
 LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2018,(22):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]

更新日期/Last Update: 2019-11-15
中国足彩网竞彩